- Home
- SNCY vs ATXS Comparison
SNCY vs ATXS Comparison
Compare SNCY & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCY
- ATXS
- Stock Information
- Founded
- SNCY 1982
- ATXS 2008
- Country
- SNCY United States
- ATXS United States
- Employees
- SNCY N/A
- ATXS N/A
- Industry
- SNCY Air Freight/Delivery Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SNCY Consumer Discretionary
- ATXS Health Care
- Exchange
- SNCY Nasdaq
- ATXS Nasdaq
- Market Cap
- SNCY 558.2M
- ATXS 669.8M
- IPO Year
- SNCY 2021
- ATXS 2015
- Fundamental
- Price
- SNCY $14.89
- ATXS $9.37
- Analyst Decision
- SNCY Buy
- ATXS Strong Buy
- Analyst Count
- SNCY 6
- ATXS 5
- Target Price
- SNCY $18.33
- ATXS $25.60
- AVG Volume (30 Days)
- SNCY 988.2K
- ATXS 219.2K
- Earning Date
- SNCY 10-30-2024
- ATXS 11-13-2024
- Dividend Yield
- SNCY N/A
- ATXS N/A
- EPS Growth
- SNCY N/A
- ATXS N/A
- EPS
- SNCY 0.82
- ATXS N/A
- Revenue
- SNCY $1,060,877,000.00
- ATXS N/A
- Revenue This Year
- SNCY $4.13
- ATXS N/A
- Revenue Next Year
- SNCY $8.33
- ATXS N/A
- P/E Ratio
- SNCY $18.23
- ATXS N/A
- Revenue Growth
- SNCY 2.87
- ATXS N/A
- 52 Week Low
- SNCY $9.22
- ATXS $4.26
- 52 Week High
- SNCY $17.56
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- SNCY 62.00
- ATXS 30.44
- Support Level
- SNCY $15.06
- ATXS $11.40
- Resistance Level
- SNCY $15.92
- ATXS $11.75
- Average True Range (ATR)
- SNCY 0.72
- ATXS 0.75
- MACD
- SNCY 0.01
- ATXS -0.23
- Stochastic Oscillator
- SNCY 71.96
- ATXS 7.64
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.